Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Medicenna Therapeutics Corp. has reported promising results from its Phase 1/2 ABILITY-1 study, showcasing significant single-agent activity of MDNA11 in patients with advanced solid tumors. The study also highlights a favorable safety profile when MDNA11 is combined with KEYTRUDA, indicating potential for enhanced cancer treatment options. These developments are promising for investors watching the biotech sector.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
